Protective Effect of Beraprost Sodium Tablets on Reperfusion Therapy for Acute STEMI

Southern University of Science and Technology

Status and phase

Unknown

Early Phase 1

Conditions

Essential Hypertension

Treatments

Drug: Beraprost Sodium Tablets

Study type

Interventional

Funder types

Other

Identifiers

NCT05103813

Beraprost Sodium treat STEMI

Details and patient eligibility

About

Protective effect of Beraprost Sodium Tablets on coronary microcirculation function and ventricular remodeling after reperfusion therapy for acute ST segment elevation myocardial infarction

Enrollment

100 estimated patients

Sex

All

Ages

18 to 70 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

It meets the diagnostic criteria of acute ST segment elevation myocardial infarction: ischemic chest pain lasts for more than 30 minutes and can not be relieved by taking nitroglycerin; ST segment elevation of ECG with two or more adjacent leads, limb lead ≥ 1mm, chest lead ≥ 2mm; Or new left bundle branch block; The serum markers of myocardial necrosis increased at least twice the normal value
Acute myocardial infarction was confirmed by coronary angiography
The clinical and angiographic data were complete
Direct PCI was performed within 12 hours after onset

Exclusion criteria

Those who do not cooperate in the inspection, have poor compliance and cannot guarantee the completion of the test
Conscious disorder, obvious intellectual disorder and mental disorder
With metal foreign bodies, such as metal prosthesis, intraocular metal foreign bodies, intracranial aneurysm clamp, etc
People with claustrophobia
Had a history of myocardial infarction, PCI and coronary artery bypass grafting
Factors affecting ST segment changes of ECG: complete left bundle branch block, preexcitation syndrome, pacemaker ECG, etc